IMPT-601 / Lyell Immunopharma - LARVOL DELTA

Efficacy of a claudin 18.2/TGFβ bi-specific CAR-T in preclinical mouse models of gastric cancer (AACR 2025) - "Claudin 18.2, a tight junction protein that is expressed on the GC cell surface, has been validated as a bona fide target in GC with recent FDA approval of zolbetuximab, a Claudin 18.2 directed antibody. We also demonstrate remodeling of the tumor immune microenvironment in our GC model in an immune competent background with an increase in CD19+ B cells in mice treated with our bispecific Claudin18.2/TGFβ CAR-T versus mice treated with untransduced T cells. Our data suggest that a bi-specific claudin18.2/TGFβ CAR T cell candidate may be an effective therapeutic approach for the treatment of gastric tumors that express Claudin 18.2."

Preclinical • Gastric Cancer • Oncology • Solid Tumor • CLDN18 • TGFB1

Therapeutic potential of IMPT-601, a Claudin18.2/TGF-β bispecific CAR, against gastric cancer (SITC 2024) - "Recent third-party Phase I clinical trials have reported efficacy of CLDN18.2 CAR T cells against GC/GEJC but improving CAR persistence in the tumor microenvironment (TME) remains a challenge. Animals treated with IMPT-601 maintained stable body weights throughout the study, suggesting IMPT-601 is well tolerated in these animals. Conclusions IMPT-601 is a potentially promising CAR T cell therapy candidate for the treatment of GC/GEJC by enabling the conversion of the immunosuppressive TGF-β into an activation signal, potentiating CAR T cells to accumulate in the immunosuppressive TME while retaining T cell fitness and reducing the frequency of regulatory T cells by dual targeting CLDN18.2 and TGF-β."

Esophageal Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Gastrointestinal Cancer • Oncology • Solid Tumor • CLDN18 • TGFB1

ImmPACT Bio to Present New Preclinical Data on Claudin18.2/TGF-β Bispecific CAR T-Cell Therapy IMPT-601 for Gastric Cancer at the SITC 39th Annual Meeting (PRNewswire) - "ImmPACT Bio USA, Inc...announced that it will present new preclinical data about the potential of IMPT-601, a Claudin18.2/transforming growth factor beta (TGF-β) bispecific CAR T-cell therapy for the treatment of gastric cancer."

Preclinical • Gastric Cancer

Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes its Pipeline to Focus on Next-Generation CAR T-cell Therapies (GlobeNewswire) - "Lyell Immunopharma...announced today that it has entered into a definitive agreement to acquire ImmPACT Bio USA....ImmPACT’s lead program, IMPT-314, is a CD19/20-targeting chimeric antigen receptor (CAR) T-cell product candidate that Lyell will continue to develop for hematologic malignancies....Upon closing, Lyell will acquire worldwide rights to ImmPACT’s pipeline, including the next- generation bispecific CD19/CD20 autologous CAR T-cell therapy...and an activating TGF-beta Claudin 18.2 CAR T-cell candidate, which is in preclinical development. Lyell will prioritize the development of IMPT-314 for patients with B-cell lymphoma....Data from ImmPACT’s multi-center Phase 1-2 clinical trial of IMPT-314 in patients with large B-cell lymphoma treated in the 3rd line CAR-naïve setting to be presented at a major medical conference later this year; initiation of a pivotal trial for IMPT-314 expected in 2025."

M&A • New trial • P1/2 data • Non-Hodgkin’s Lymphoma

ImmPACT Bio to Present New Ex Vivo Preclinical Data for Bispecific Claudin 18.2/TGF-β CAR T Program at the American Society of Gene & Cell Therapy 27th Annual Meeting (PRNewswire) - "ImmPACT Bio...announced that it will present new ex vivo preclinical data for ImmPACT Bio's bispecific Claudin 18.2 (CLDN18.2)/TGF-β chimeric antigen receptor (CAR) T program for the treatment of solid tumors that express CLDN18.2, including gastric and gastroesophageal junction cancer, as part of a poster presentation at the upcoming American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting....Novel dual CAR approach is designed to enhance CAR T-cell activity in solid tumors by addressing immune suppression in the tumor microenvironment."

Preclinical • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma